We’re excited to share that Cizzle Biotechnology has successfully raised £0.62 million through the issuance of new shares, marking a significant step in advancing medical innovations. This fundraising will accelerate the development and commercialization of the CIZ1B biomarker test, crucial for early-stage lung cancer detection.
Key Achievements:
- Financial Boost: Raised £0.62 million to propel forward the CIZ1B project.
- Strategic Partnership: Appointment of Allenby Capital as joint broker to enhance financial strategies.
For more details on this strategic development, visit: Cizzle Bio, Inc.